Elevance Health, Inc. $ELV Stock: South Dakota Investment Council Lowers Holdings

South Dakota Investment Council reduced its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 13.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,626 shares of the company’s stock after selling 13,209 shares during the quarter. Elevance Health accounts for approximately 0.6% of South Dakota Investment Council’s investment portfolio, making the stock its 27th biggest holding. South Dakota Investment Council’s holdings in Elevance Health were worth $34,071,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rothschild Investment LLC lifted its stake in Elevance Health by 162.6% in the third quarter. Rothschild Investment LLC now owns 3,761 shares of the company’s stock valued at $1,462,000 after acquiring an additional 2,329 shares during the last quarter. Sompo Asset Management Co. Ltd. grew its position in shares of Elevance Health by 29.3% in the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 1,616 shares of the company’s stock valued at $628,000 after acquiring an additional 366 shares during the period. Ironwood Investment Counsel LLC grew its position in shares of Elevance Health by 1.9% in the 3rd quarter. Ironwood Investment Counsel LLC now owns 12,620 shares of the company’s stock valued at $4,907,000 after acquiring an additional 234 shares during the period. Edgestream Partners L.P. acquired a new position in shares of Elevance Health during the 3rd quarter worth about $609,000. Finally, Banco Santander S.A. increased its stake in shares of Elevance Health by 26.0% during the 3rd quarter. Banco Santander S.A. now owns 13,663 shares of the company’s stock worth $5,312,000 after purchasing an additional 2,818 shares during the last quarter. 89.24% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ELV. UBS Group upped their target price on shares of Elevance Health from $460.00 to $523.00 and gave the company a “buy” rating in a report on Thursday, October 22nd. Mizuho set a $490.00 price target on Elevance Health in a report on Friday, October 23rd. Robert W. Baird lifted their price target on Elevance Health from $393.00 to $406.00 and gave the stock a “neutral” rating in a report on Thursday, October 22nd. Royal Bank Of Canada boosted their price target on Elevance Health from $424.00 to $455.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Elevance Health in a research note on Wednesday, November 11th. Fifteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $456.48.

Read Our Latest Stock Report on Elevance Health

Insiders Place Their Bets

In other news, EVP Ratnakar Lavu sold 1,300 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $440.00, for a total transaction of $572,000.00. Following the completion of the sale, the executive vice president directly owned 14,849 shares in the company, valued at approximately $6,533,560. This represents a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Mark Kaye sold 10,584 shares of the company’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the sale, the chief financial officer owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.34% of the stock is owned by company insiders.

Elevance Health Stock Performance

NYSE ELV opened at $434.47 on Wednesday. The firm has a 50-day moving average price of $416.83 and a two-hundred day moving average price of $376.16. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $450.69. The company has a market capitalization of $93.87 billion, a P/E ratio of 18.53, a P/E/G ratio of 2.13 and a beta of 0.63. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV – Get Free Report) last announced its earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, topping the consensus estimate of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company had revenue of $50.44 billion for the quarter, compared to analysts’ expectations of $49.28 billion. During the same period last year, the firm earned $6.03 earnings per share. The business’s revenue for the quarter was up .7% on a year-over-year basis. Analysts anticipate that Elevance Health, Inc. will post 29.15 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health’s dividend payout ratio is currently 29.34%.

Elevance Health Profile

(Free Report)

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

See Also

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.